Trial Profile
A randomised, double-blind study comparing the efficacy and safety of 145 mg fenofibrate, 10 mg Ezetimibe and their combination in patients with type IIb dyslipidemia and features of the metabolic syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jul 2011
Price :
$35
*
At a glance
- Drugs Fenofibrate (Primary) ; Ezetimibe
- Indications Dyslipidaemias; Hyperlipidaemia; Lipid metabolism disorders; Metabolic syndrome
- Focus Therapeutic Use
- Sponsors Laboratorios Fournier
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2004-002408-13).
- 20 Apr 2010 Actual patient numbers amended from (186) to (181) as reported by ClinicalTrials.gov.
- 11 May 2007 Status change from in progress to completed.